IP Library Granted Patent US 10,065,963
Granted Patent B2
US 10,065,963 · App. 15/343,375 · Granted Sep 4, 2018

Heterocyclic compounds as PI3K-γ inhibitors

Inventors: Artem Shvartsbart (Kennett Square, PA); Stacey Shepard (Wilmington, DE); Andrew P. Combs (Kennett Square, PA); Lixin Shao (Wilmington, DE); Nikoo Falahatpisheh (Wilmington, DE); Ge Zou (Greenville, DE); Eddy W. Yue (Landenberg, PA); Ravi Kumar Jalluri (Avondale, PA)
Assignee: Incyte Corporation
C07D487/04C07D519/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,065,963
App. No.
15/343,375
Granted
Sep 4, 2018
Kind
B2
Abstract

This application relates to compounds of Formula (I): or pharmaceutically acceptable salts or stereoisomers thereof, which are inhibitors of PI3K-γ which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.

Claims (14)

1. A compound, which is 2-amino-N-(1-[8-chloro-5-(2-methyl-1, 1-dioxidothiomorpholin-4-yl)imidazo[1,5-a]pyridin-6-yl]ethyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide, or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , which is 2-amino-N-((1S)-1-(8-chloro-5-(2-methyl-1,1-dioxidothiomorpholino)imidazo[1,5-a]pyridin-6-yl)ethyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide, or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1 , which is 2-amino-N—((S)-1-(8-chloro-5-((R)-2-methyl-1,1-dioxidothiomorpholino)imidazo [1,5-a]pyridin-6-yl)ethyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide, or a pharmaceutically acceptable salt thereof.

4. The compound of claim 1 , which is 2-amino-N—((S)-1-(8-chloro-5-((S)-2-methyl-1,1-dioxidothiomorpholino)imidazo [1,5-a]pyridin-6-yl)ethyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide, or a pharmaceutically acceptable salt thereof.

5. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or carrier.

6. A pharmaceutical composition comprising a compound of claim 2 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or carrier.

7. A pharmaceutical composition comprising a compound of claim 3 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or carrier.

8. A pharmaceutical composition comprising a compound of claim 4 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or carrier.

9. A compound, which is 2-amino-N-{1-[8-chloro-1-cyano-5-(1,1-dioxidothiomorpholin-4-yl)imidazo[1, 5-a]pyridin-6-yl]ethyl}pyrazolo [1,5-a]pyrimidine-3-carboxamide, or a pharmaceutically acceptable salt thereof.

10. A pharmaceutical composition comprising a compound of claim 9 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or carrier.

11. A compound, which is 2-amino-N-(1-(8-chloro-1-cyano-5-(2-methyl-1,1-dioxidothiomorpholino)imidazo[1, 5-a]pyridin-6-yl)ethyl)pyrazolo [1,5-a]pyrimidine-3-carboxamide, or a pharmaceutically acceptable salt thereof.

12. A pharmaceutical composition comprising a compound of claim 11 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or carrier.

13. A compound, which is 2-amino-N-(1-(8-chloro-1-cyano-5-(2-methyl-1,1-dioxidothiomorpholino)imidazo[1, 5-a]pyridin-6-yl)propyl)pyrazolo [1,5-a]pyrimidine-3-carboxamide, or a pharmaceutically acceptable salt thereof.

14. A pharmaceutical composition comprising a compound of claim 13 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or carrier.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 17, 2017
From: SHVARTSBART, ARTEM; SHEPARD, STACEY; COMBS, ANDREW P.; SHAO, LIXIN; FALAHATPISHEH, NIKOO; ZOU, GE; BUESKING, ANDREW W.; SPARKS, RICHARD B.; YUE, EDDY W.; JALLURI, RAVI KUMAR
To: INCYTE CORPORATION
Reel/Frame 042412/0009 →
Continuity (2)
Provisional Application 62252050 · Nov 6, 2015
Related Publication 20170129899A1 · May 11, 2017
Cited By (2)
US 12,410,170 US 12,516,065